Access, Prescribing and Costs
Ireland's medical cannabis access programme: what patients should know
Ireland has a formal medical cannabis access pathway, but it is narrow and specialist-led. That matters because patients often hear about access programmes in the abstract without the clinical limits that go with them.
Ireland has a formal medical cannabis access pathway, but it is narrow and specialist-led. That matters because patients often hear about access programmes in the abstract without the clinical limits that go with them.
The key point is that Ireland's system is not "medical cannabis for anyone who asks". It is a controlled programme for specific indications.
Key takeaways
- Ireland's access programme is limited to a small number of conditions.
- Consultant-led prescribing is central to the pathway.
- The reimbursement scheme helps with funding for approved products.
- A cross-border comparison should not be mistaken for UK eligibility.
Evidence base
The Irish Department of Health says the Medical Cannabis Access Programme was set up to facilitate access under defined legislation and guidance. HSE guidance says the Medical Cannabis Products Reimbursement Scheme helps patients apply for funding for cannabis-based products prescribed by a consultant.
Official Irish guidance also says the programme covers only a few indications, including spasticity associated with multiple sclerosis, intractable nausea and vomiting associated with chemotherapy, and severe refractory epilepsy. In 2026, the Department of Health announced a review of access to cannabis for medical use, which shows the policy is still under active review.
What patients should know
If you are in Ireland and think you may qualify, the first step is a consultant discussion, not a general online store search. If you are in the UK and reading about Ireland, remember that eligibility, reimbursement, and legal rules differ between countries.
Do not treat a headline about an access programme as proof that any cannabis product will help. The real issue is whether a specialist considers the product, the condition, and the monitoring plan appropriate.
When to speak to a clinician
- You think you may meet one of the Irish programme indications.
- You need help understanding reimbursement or application steps.
- You are comparing Irish access with UK medical cannabis rules.
- You need clarity about consultant-only prescribing.
- You are unsure whether a product is actually covered by the programme.